Zimmer in frame for number-two ortho spot with $13bn Biomet buy
This article was originally published in Clinica
Just over a month after saying it was going public again, Biomet is now to be acquired by number-three orthopedic player Zimmer for $13.35bn in a combination of cash and stock. Warsaw, Indiana-based Biomet was ranked number 6 in Clinica’s Top 20 Orthopedics league table last year, and the purchase looks set to catapult Zimmer to the number-two position in the market. It is also easily the biggest buy of 2014 so far.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.